Premium
Fluorodeoxyglucose positron emission tomography (FDG‐PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS)
Author(s) -
Rao V. Koneti,
Carrasquillo Jorge A.,
Dale Janet K.,
Bacharach Stephen L.,
Whatley Millie,
Dugan Faith,
Tretler Jean,
Fleisher Thomas,
Puck Jennifer M.,
Wilson Wyndham,
Jaffe Elaine S.,
Avila Nilo,
Chen Clara C.,
Straus Stephen E.
Publication year - 2006
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20523
Subject(s) - autoimmune lymphoproliferative syndrome , medicine , positron emission tomography , lymphoma , hepatosplenomegaly , fluorodeoxyglucose , pathology , lymphoproliferative disorders , radiology , apoptosis , disease , biology , biochemistry , programmed cell death , fas receptor
Autoimmune lymphoproliferative syndrome (ALPS) is associated with mutations that impair the activity of lymphocyte apoptosis proteins, leading to chronic lymphadenopathy, hepatosplenomegaly, autoimmunity, and an increased risk of lymphoma. We investigated the utility of fluorodeoxyglucose positron emission tomography (FDG‐PET) in discriminating benign from malignant lymphadenopathy in ALPS. We report that FDG avidity of benign lymph nodes in ALPS can be high and, hence, by itself does not imply presence of lymphoma; but FDG‐PET can help guide the decision for selecting which of many enlarged nodes in ALPS patients to biopsy when lymphoma is suspected. Am. J. Hematol. 81:81–85, 2006. © 2006 Wiley‐Liss, Inc.